Case study: Novel development in immune therapy against influenza A groups 1 and 2

Email address:

First name:

Last name:

Job title:

Company name:

Country:

I work for

Please specify your industry *

please check before submitting

Mobile number:

What is your role?

Subscribe to VaccineNation Newsletter?

Unfortunately the document is not available at this current time, however if you leave your details we'll get it to you as soon as we can.

Please fill in all the information requested. It is very important you enter this information correctly so we can contact you with the document.

Privacy statement »

Manage your email preferences »

Remember my details Information

Remember my details

We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

close »

The goal of all vaccine production, influenza vaccines included, is improved vaccines for all by increasing the breath of protection for longer lasting immunity. One such possible method to achieve this is the use of mAb (Monoclonal Antibodies) in vaccine production. Why not download this case study to discover more about this use of mAbs in the production of an Influenza vaccine.

Robert Friesen, VP Pre-clinical & Clinical Research, Crucell joined us at the World Influenza Congress to give details on the novel development in immune theraphy against influenza A groups 1 and 2.

Why not download the case study Novel development in immune therapy against influenza A groups 1 and 2 and discover more about:
• Discovery of broadly neutralising human mAbs against group 1 and 2 Influenza strains
• Functional and structural characterization of mechanisms of neutralization
• Prevention and treatment studies in Influenza animal disease models

Case study: Novel development in immune therapy against influenza A groups 1 and 2

information we require

please check before submitting